Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies

Medicine and Dentistry

• Mechanistic Target of Rapamycin 100%
• Pancreas Cancer 100%
• Phosphoinositide 3-Kinase 50%
• Erlotinib 50%
• Disease 33%
• Cancer Cell 33%
• Overall Survival 33%
• Disease Exacerbation 33%
• Rapamycin 33%
• Negative Feedback 33%
• Mammalian Target of Rapamycin Inhibitor 33%
• Neoplasm 16%
• Biopsy 16%
• Long Term Exposure 16%
• Diarrhea 16%
• Nausea 16%
• Oncology 16%
• Neutropenia 16%
• Hyperglycemia 16%
• In Vitro 16%
• Tumor Model 16%
• Asthenia 16%
• Antineoplastic Activity 16%
• Cerebral Hemorrhage 16%
• Biological Marker 16%
• Cyclin D1 16%
• Exanthem 16%
• Cholangitis 16%
• Mediator 16%
• Progression Free Survival 16%
• Progressive Disease 16%
• Tumor Biopsy 16%
• Immunofluorescence 16%
• Everolimus 16%
• Mucositis 16%
• Laser Scanning Cytometry 16%
• Hyponatremia 16%
• Electrocorticography 16%
• Temsirolimus 16%
• Boron Neutron Capture Therapy 16%
• Insulin Receptor Substrate 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Mammalian Target of Rapamycin 100%
• Pancreas Cancer 100%
• Disease 50%
• Phosphatidylinositol 3 Kinase 50%
• Erlotinib 50%
• Neoplasm 33%
• Disease Exacerbation 33%
• Overall Survival 33%
• Rapamycin 33%
• Mammalian Target of Rapamycin Inhibitor 33%
• Long Term Exposure 16%
• Rash 16%
• Nausea 16%
• Hyperglycemia 16%
• Brain Hemorrhage 16%
• Biological Marker 16%
• Asthenia 16%
• Diarrhea 16%
• Antitumor Activity 16%
• Cyclin D1 16%
• Progression Free Survival 16%
• Everolimus 16%
• Temsirolimus 16%
• Neutropenia 16%
• Hyponatremia 16%
• Tumor Model 16%
• Mucosa Inflammation 16%
• Insulin Receptor Substrate 16%
• Cholangitis 16%

Keyphrases

• Hepatic Parameters 33%
• Renal Parameters 33%